DZ3402A1 - Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement - Google Patents

Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Info

Publication number: DZ3402A1
Authority: DZ; Algeria
Prior art keywords: treatment; cyclopentanoindoles; methods; same; compositions containing
Prior art date: 2000-07-25

Application number

DZ013402A

Other languages

English (en)

Inventor

Marc Labelle

Claudio Sturino

Bruno Roy

Carl Berthelette

Michael Boyd

Nicolas Lachance

John Scheigetz

Original Assignee

Merck Frosst Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-25

Filing date

2001-07-23

Publication date

2002-01-31

2001-07-23 Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc

2002-01-31 Application granted granted Critical

2002-01-31 Publication of DZ3402A1 publication Critical patent/DZ3402A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/38—TPC being performed in particular situations
- H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04B—TRANSMISSION
- H04B17/00—Monitoring; Testing
- H04B17/30—Monitoring; Testing of propagation channels
- H04B17/309—Measuring or estimating channel quality parameters
- H04B17/318—Received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/02—Access restriction performed under specific conditions
- H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/06—TPC algorithms
- H04W52/14—Separate analysis of uplink or downlink
- H04W52/146—Uplink power control
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
- H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/20—Selecting an access point
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
- H04W52/04—TPC
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Signal Processing (AREA)
Computer Networks & Wireless Communication (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Quality & Reliability (AREA)
Physics & Mathematics (AREA)
Electromagnetism (AREA)
Computer Security & Cryptography (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Steroid Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Materials For Photolithography (AREA)

DZ013402A 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement DZ3402A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US22068300P	2000-07-25	2000-07-25

Publications (1)

Publication Number	Publication Date
DZ3402A1 true DZ3402A1 (fr)	2002-01-31

Family

ID=22824535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ013402A DZ3402A1 (fr)	2000-07-25	2001-07-23	Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement

Country Status (34)

Country	Link
US (1)	US6410583B1 (fr)
EP (1)	EP1305286B1 (fr)
JP (1)	JP4119745B2 (fr)
KR (1)	KR100746814B1 (fr)
CN (1)	CN1214007C (fr)
AT (1)	ATE284388T1 (fr)
AU (2)	AU2001277430B2 (fr)
BG (1)	BG66084B1 (fr)
BR (1)	BR0112756A (fr)
CA (1)	CA2416867C (fr)
CZ (1)	CZ2003236A3 (fr)
DE (1)	DE60107687T2 (fr)
DK (1)	DK1305286T3 (fr)
DZ (1)	DZ3402A1 (fr)
EA (1)	EA006765B1 (fr)
EC (1)	ECSP034428A (fr)
EE (1)	EE05287B1 (fr)
ES (1)	ES2231526T3 (fr)
GE (1)	GEP20053595B (fr)
HK (1)	HK1058934A1 (fr)
HR (1)	HRP20021039B1 (fr)
HU (1)	HUP0301745A3 (fr)
IL (2)	IL153406A0 (fr)
IS (1)	IS2170B (fr)
MX (1)	MXPA03000710A (fr)
NO (1)	NO325011B1 (fr)
NZ (1)	NZ523106A (fr)
PL (1)	PL207342B1 (fr)
PT (1)	PT1305286E (fr)
RS (1)	RS50491B (fr)
SK (1)	SK287507B6 (fr)
UA (1)	UA73787C2 (fr)
WO (1)	WO2002008186A2 (fr)
ZA (1)	ZA200300554B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US6784172B2 (en)	2000-11-03	2004-08-31	Wyeth	Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031200A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031199A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031195A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
ES2230382T3 (es) *	2000-11-03	2005-05-01	Wyeth	Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
US7141563B2 (en)	2000-11-03	2006-11-28	Wyeth	Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031202A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307682A (en)	2002-04-25	2003-12-16	Wyeth Corp	1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en)	2002-04-25	2009-08-01		[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en)	2002-04-25	2003-12-16	Wyeth Corp	[1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200400963A (en)	2002-05-21	2004-01-16	Wyeth Corp	R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200400818A (en)	2002-05-21	2004-01-16	Wyeth Corp	Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
CN1791577A (zh) *	2003-05-20	2006-06-21	麦克弗罗斯特加拿大有限公司	氟－甲基磺酰取代的环烷并吲哚和它们作为前列腺素d2拮抗剂的用途
JP2006527205A (ja) *	2003-06-12	2006-11-30	メルクフロストカナダリミテツド	Ｄｐ受容体拮抗物質としてのシクロアルカンピロロピリジン
US20080153817A1 (en) *	2003-08-07	2008-06-26	Dirk Beher	Treatment for Alzheimer's Disease and Related Conditions
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2006008119A1 (fr)	2004-07-16	2006-01-26	Proteosys Ag	Antagonistes muscariniques avec activite modulatrice parp et sin en tant qu'agents contre les maladies inflammatoires
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es)	2004-11-05	2006-10-27		Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
US20090054423A1 (en) *	2005-04-13	2009-02-26	Imbriglio Jason E	Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en)	2005-05-02	2011-03-08	Wandzel Richard A	Treatment of congestion using steroids and adrenergics
AR054849A1 (es)	2005-07-26	2007-07-18	Wyeth Corp	Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) *	2007-02-08	2010-10-14	Paolini John F	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
KR20190004843A (ko) *	2008-07-23	2019-01-14	아레나 파마슈티칼스, 인크.	자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
NZ591001A (en)	2008-08-27	2012-11-30	Arena Pharm Inc	Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
WO2010030360A1 (fr)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	Dérivés 3h-imidazo[4,5-b]pyridin-5-ol utiles dans le traitement de troubles du récepteur gpr81
AU2009295308A1 (en) *	2008-09-25	2010-04-01	Merck Canada Inc.	Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists
WO2010081825A2 (fr)	2009-01-13	2010-07-22	Proteosys Ag	Pirenzépine en tant qu'agent utilisé dans le traitement du cancer
EP2493881A1 (fr)	2009-10-26	2012-09-05	Bayer CropScience AG	Nouvelle forme solide de 4-[[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino]furan-2(5h)-one
SG10201500639TA (en)	2010-01-27	2015-03-30	Arena Pharm Inc	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en)	2010-03-03	2015-04-29	Arena Pharm Inc	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2912458B1 (fr)	2012-10-24	2018-07-18	NYU Winthrop Hospital	Biomarqueurs non-invasifs pour identifier les sujets à risque d'accouchement prématuré
JP6895378B2 (ja)	2015-01-06	2021-06-30	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態の処置方法
WO2016128565A1 (fr) *	2015-02-13	2016-08-18	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Antagonistes de ptgdr-1 et/ou de ptgdr-2 pour la prévention et/ou le traitement du lupus érythémateux systémique
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
KR20190116416A (ko)	2017-02-16	2019-10-14	아레나 파마슈티칼스, 인크.	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR20190113955A (ko)	2017-02-16	2019-10-08	아레나 파마슈티칼스, 인크.	장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
WO2019055661A1 (fr)	2017-09-13	2019-03-21	Progenity, Inc.	Biomarqueurs de pré-éclampsie ainsi que systèmes et procédés associés
US11279656B2 (en)	2017-10-27	2022-03-22	Applied Materials, Inc.	Nanopowders, nanoceramic materials and methods of making and use thereof
KR20210074291A (ko)	2018-09-06	2021-06-21	아레나 파마슈티칼스, 인크.	자가면역 및 염증성 장애의 치료에 유용한 화합물
EP4070113A4 (fr)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN115260173B (zh) *	2021-04-30	2024-08-30	厦门宝太生物科技股份有限公司	环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) *	2023-07-10	2023-10-10	青岛科技大学	一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr)	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en)	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en)	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3768097D1 (de)	1986-01-23	1991-04-04	Merck Frosst Canada Inc	Tetrahydrocarbazol-1-alkansaeuren.
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
NZ310559A (en) *	1995-06-21	1999-05-28	Shionogi & Co	Bicyclic sulphonamide and carboxamide derivatives and medicaments
CZ297324B6 (cs) *	1996-12-13	2006-11-15	Shionogi & Co., Ltd.	Benzothiofenkarboxamidové deriváty a antagonisty PGD2, které je obsahují
EP1084711B1 (fr) *	1998-06-03	2005-05-11	Shionogi & Co., Ltd.	Remedes contre le prurit renfermant des antagonistes de pgd2

2001
- 2001-07-20 US US09/909,636 patent/US6410583B1/en not_active Expired - Lifetime
- 2001-07-23 PT PT01955162T patent/PT1305286E/pt unknown
- 2001-07-23 IL IL15340601A patent/IL153406A0/xx active IP Right Grant
- 2001-07-23 HU HU0301745A patent/HUP0301745A3/hu unknown
- 2001-07-23 NZ NZ523106A patent/NZ523106A/en not_active IP Right Cessation
- 2001-07-23 GE GE5105A patent/GEP20053595B/en unknown
- 2001-07-23 MX MXPA03000710A patent/MXPA03000710A/es active IP Right Grant
- 2001-07-23 RS YUP-979/02A patent/RS50491B/sr unknown
- 2001-07-23 DE DE60107687T patent/DE60107687T2/de not_active Expired - Lifetime
- 2001-07-23 CA CA002416867A patent/CA2416867C/fr not_active Expired - Fee Related
- 2001-07-23 DK DK01955162T patent/DK1305286T3/da active
- 2001-07-23 AU AU2001277430A patent/AU2001277430B2/en not_active Expired
- 2001-07-23 CN CNB018131662A patent/CN1214007C/zh not_active Expired - Fee Related
- 2001-07-23 EP EP01955162A patent/EP1305286B1/fr not_active Expired - Lifetime
- 2001-07-23 BR BR0112756-0A patent/BR0112756A/pt active Search and Examination
- 2001-07-23 EA EA200300171A patent/EA006765B1/ru not_active IP Right Cessation
- 2001-07-23 CZ CZ2003236A patent/CZ2003236A3/cs unknown
- 2001-07-23 WO PCT/CA2001/001069 patent/WO2002008186A2/fr active IP Right Grant
- 2001-07-23 AT AT01955162T patent/ATE284388T1/de active
- 2001-07-23 KR KR1020037001117A patent/KR100746814B1/ko active IP Right Grant
- 2001-07-23 AU AU7743001A patent/AU7743001A/xx active Pending
- 2001-07-23 UA UA2003021565A patent/UA73787C2/uk unknown
- 2001-07-23 JP JP2002514093A patent/JP4119745B2/ja not_active Expired - Fee Related
- 2001-07-23 EE EEP200300033A patent/EE05287B1/xx not_active IP Right Cessation
- 2001-07-23 SK SK93-2003A patent/SK287507B6/sk not_active IP Right Cessation
- 2001-07-23 ES ES01955162T patent/ES2231526T3/es not_active Expired - Lifetime
- 2001-07-23 PL PL363168A patent/PL207342B1/pl not_active IP Right Cessation
- 2001-07-23 DZ DZ013402A patent/DZ3402A1/fr active
2002
- 2002-12-12 IS IS6655A patent/IS2170B/is unknown
- 2002-12-12 IL IL153406A patent/IL153406A/en not_active IP Right Cessation
- 2002-12-30 HR HR20021039A patent/HRP20021039B1/xx not_active IP Right Cessation
2003
- 2003-01-06 BG BG107438A patent/BG66084B1/bg unknown
- 2003-01-13 EC EC2003004428A patent/ECSP034428A/es unknown
- 2003-01-21 ZA ZA200300554A patent/ZA200300554B/en unknown
- 2003-01-24 NO NO20030374A patent/NO325011B1/no not_active IP Right Cessation
2004
- 2004-03-11 HK HK04101796A patent/HK1058934A1/xx unknown

Also Published As

Publication number	Publication date
NO20030374D0 (no)	2003-01-24
IL153406A (en)	2008-03-20
ZA200300554B (en)	2004-04-23
PT1305286E (pt)	2005-04-29
HUP0301745A3 (en)	2010-03-29
DE60107687T2 (de)	2005-12-01
YU97902A (sh)	2006-05-25
PL207342B1 (pl)	2010-12-31
BG66084B1 (bg)	2011-03-31
AU2001277430B2 (en)	2006-05-25
CA2416867A1 (fr)	2002-01-31
HRP20021039A2 (en)	2004-10-31
DK1305286T3 (da)	2005-03-14
HRP20021039B1 (en)	2011-03-31
CN1443165A (zh)	2003-09-17
JP4119745B2 (ja)	2008-07-16
BG107438A (bg)	2003-09-30
US6410583B1 (en)	2002-06-25
AU7743001A (en)	2002-02-05
NO20030374L (no)	2003-01-24
DE60107687D1 (de)	2005-01-13
EA200300171A1 (ru)	2003-06-26
SK932003A3 (en)	2003-06-03
NZ523106A (en)	2005-01-28
BR0112756A (pt)	2003-06-24
CA2416867C (fr)	2008-03-25
ECSP034428A (es)	2003-03-10
WO2002008186A2 (fr)	2002-01-31
GEP20053595B (en)	2005-08-10
RS50491B (sr)	2010-03-02
PL363168A1 (en)	2004-11-15
EP1305286A2 (fr)	2003-05-02
IL153406A0 (en)	2003-07-06
IS2170B (is)	2006-11-15
CZ2003236A3 (cs)	2003-05-14
KR20030024810A (ko)	2003-03-26
EE200300033A (et)	2004-10-15
HUP0301745A2 (hu)	2003-09-29
SK287507B6 (sk)	2010-12-07
EP1305286B1 (fr)	2004-12-08
NO325011B1 (no)	2008-01-14
HK1058934A1 (en)	2004-06-11
JP2004504380A (ja)	2004-02-12
EA006765B1 (ru)	2006-04-28
ATE284388T1 (de)	2004-12-15
KR100746814B1 (ko)	2007-08-06
EE05287B1 (et)	2010-04-15
WO2002008186A3 (fr)	2002-03-21
MXPA03000710A (es)	2003-06-04
IS6655A (is)	2002-12-12
UA73787C2 (en)	2005-09-15
CN1214007C (zh)	2005-08-10
ES2231526T3 (es)	2005-05-16

Publication	Publication Date	Title
DZ3402A1 (fr)	2002-01-31	Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
JO2481B1 (en)	2009-01-20	Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
BR0113286B1 (pt)	2013-04-16	pirazàis substituÍdos e composiÇço farmacÊutica compreendendo os mesmos.
NO20030845D0 (no)	2003-02-24	Utvalgte fusjonerte pyrrolokarbazoler
DZ3265A1 (fr)	2000-10-19	Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
IS4695A (is)	1998-03-20	(Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
CY1106032T1 (el)	2011-04-06	Υποκατασταθεισες πυραζολες
ES2171723T3 (es)	2002-09-16	3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
CY1105039T1 (el)	2010-03-03	ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
ES2243579T3 (es)	2005-12-01	Derivados de pirazolopirideno.
TNSN06012A1 (en)	2007-10-03	Emulsifying systems containing azetidine derivatives
YU39201A (sh)	2004-07-15	Upotreba 1-arilpirazola za pripremanje oralnog sredstva za suzbijanje parazita
SE9801494D0 (sv)	1998-04-28	Novel use
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
ATE290857T1 (de)	2005-04-15	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200494T2 (tr)	2003-02-21	Yağlı asit sintazı inhibitörleri.
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
CY1111290T1 (el)	2015-08-05	Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE0001631D0 (sv)	2000-05-04	New use
SE0002045D0 (sv)	2000-05-31	New use
MXPA03003466A (es)	2004-09-10	Derivados de piranosido.
CR20120385A (es)	2012-09-13	Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)